PMID: 7541280Apr 1, 1995Paper

Functional interaction between losartan and central tachykinin NK3 receptors in the conscious rat

British Journal of Pharmacology
P PicardR Couture

Abstract

1. The cardiovascular and behavioural effects elicted by the intracerebroventricular (i.c.v.) injection of substance P (SP), neurokinin A (NKA), [MePhe7]neurokinin B ([MePhe7]NKB) or angiotensin II (AII) in the conscious rat were assessed before and 5 min after i.c.v. pretreatment with antagonists selective for angiotensin AT1 (losartan and its active metabolite EXP 3174), angiotensin AT2 (PD 123,319) or tachykinin NK3 (R 486) receptors. 2. I.c.v. administration of 25 pmol AII evoked an increase in mean arterial blood pressure (MAP) and water intake behaviour, accompanied by a transient bradycardia, whereas 25 pmol [MePhe7]NKB caused a transient increase in MAP and heart rate (HR) concurrently with marked wet dog shake behaviour. At the same dose, SP and NKA were more potent than [MePhe7]NKB in increasing MAP and HR, but did not produce water intake or wet dog shake behaviours. 3. Losartan (650 pmol, i.c.v.) reduced significantly the cardiovascular and behavioural responses to AII or [MePhe7]NKB, but not to SP or NKA. While 65 pmol losartan was inactive, 260 pmol inhibited selectively the central effects of AII. Whereas EXP 3174 (6.5 nmol) blocked both AII and [MePhe7]NKB-mediated responses, the dose of 650 pmol blocked only th...Continue Reading

References

May 15, 1992·Biochemical and Biophysical Research Communications·C AdvenierD Regoli
Sep 1, 1992·Brain Research. Brain Research Reviews·J W Wright, J W Harding
Mar 22, 1992·The Journal of Comparative Neurology·J MarksteinerJ E Krause
Jul 1, 1992·Trends in Pharmacological Sciences·K J Watling
Mar 1, 1992·Medicinal Research Reviews·J V DunciaP B Timmermans
Jan 25, 1991·Science·R M SniderR W Spencer
Nov 15, 1991·Proceedings of the National Academy of Sciences of the United States of America·C GarretP M Laduron
Dec 1, 1991·British Journal of Pharmacology·K F SongF A Mendelsohn
Jan 1, 1991·Annual Review of Neuroscience·S Nakanishi
Sep 1, 1991·Brain Research Bulletin·A N Epstein
Jan 1, 1991·Physiological Reviews·J A Herd
Feb 1, 1991·Trends in Pharmacological Sciences·P B TimmermansW F Herblin
Sep 1, 1990·Brain Research Bulletin·J K WamsleyM Hunt
Aug 27, 1986·Brain Research·P J Elliott, S D Iversen
Jan 1, 1988·Annual Review of Physiology·R D Foreman, R W Blair
Apr 1, 1993·Physiological Reviews·M Otsuka, K Yoshioka
Jul 1, 1993·Proceedings of the National Academy of Sciences of the United States of America·U GetherT W Schwartz
Jul 19, 1994·Proceedings of the National Academy of Sciences of the United States of America·H T SchambyeT W Schwartz

❮ Previous
Next ❯

Citations

Nov 20, 2004·Psychopharmacology·Daniel S KerrMartín Cammarota
Oct 31, 1998·Brain Research·Z Xu, A K Johnson
Dec 12, 2001·Toxicon : Official Journal of the International Society on Toxinology·Steven D Aird
Apr 5, 2003·The International Journal of Biochemistry & Cell Biology·A H Jan Danser
Oct 30, 2012·Physiology & Behavior·S DucheminH Girouard
May 16, 2006·Hormones and Behavior·Juliana S BoniniMartín Cammarota
Aug 10, 2005·Journal of the Renin-angiotensin-aldosterone System : JRAAS·John L Reid
Apr 20, 2002·Circulation Research·Junichi Sadoshima
Jan 12, 2020·Physiological Reports·Aline Maria Arlindo De SouzaRodrigo C A De Menezes

❮ Previous
Next ❯

Related Concepts

Related Feeds

Bradyarrhythmias

Bradyarrhythmias are slow heart rates. Symptoms may include syncope, dizziness, fatigure, shortness of breath, and chest pains. Find the latest research on bradyarrhythmias here.